Journal article
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN).
Abstract
PURPOSE: Despite undergoing allogeneic hematopoietic stem cell transplantation (HCT), patients with acute myeloid leukemia (AML) with internal tandem duplication mutation in the FMS-like tyrosine kinase 3 gene (FLT3-ITD) have a poor prognosis, frequently relapse, and die as a result of AML. It is currently unknown whether a maintenance therapy using FLT3 inhibitors, such as the multitargeted tyrosine kinase inhibitor sorafenib, improves outcome …
Authors
Burchert A; Bug G; Fritz LV; Finke J; Stelljes M; Röllig C; Wollmer E; Wäsch R; Bornhäuser M; Berg T
Journal
Journal of Clinical Oncology, Vol. 38, No. 26, pp. 2993–3002
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
September 10, 2020
DOI
10.1200/jco.19.03345
ISSN
0732-183X
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdolescentAdultAgedAntineoplastic AgentsChemotherapy, AdjuvantDouble-Blind MethodFemaleGermanyHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteMaintenance ChemotherapyMaleMiddle AgedMutationNeoplasm, ResidualProtein Kinase InhibitorsRecurrenceSorafenibTandem Repeat SequencesTime FactorsTransplantation, HomologousTreatment OutcomeYoung Adultfms-Like Tyrosine Kinase 3